Noida Chronicle

Myelodysplastic Syndrome Market Analysis, Market Size, Epidemiology, Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Myelodysplastic Syndrome Market Analysis, Market Size, Epidemiology, Companies, Drugs and Competitive Analysis by DelveInsight

July 14
18:04 2020
Myelodysplastic Syndrome Market Analysis, Market Size, Epidemiology, Companies, Drugs and Competitive Analysis by DelveInsight

“Myelodysplastic Syndrome Market Insights, Epidemiology and Market Forecast-2030.”

(Albany, US) DelveInsight launched a new report on “Myelodysplastic Syndrome Market Insights, Epidemiology and Market Forecast-2030.”

 

DelveInsight’s Myelodysplastic Syndrome – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts of the report

1. Myelodysplastic Syndrome was reported very rare in young people with an incident rate of less than 1 per 100,000 before age 50 years and approximately 2 per 100,000 between ages 50 and 60 years.

2. Myelodysplastic Syndrome incidence rises significantly after age 60 years: approximately 8 per 100,000 between ages 60 and 70 years and greater than 20 per 100,000 after age 70 years.

3. The rate of diagnosis is consistently high in the United States.

4. The United States has the highest percentage of incident patients.

5. Spain has consistently shown lowest treatable population among EU5.

 

Key benefits of the report

1. Myelodysplastic Syndrome market report covers a descriptive overview and comprehensive insight of the Myelodysplastic Syndrome epidemiology and Myelodysplastic Syndrome market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Myelodysplastic Syndrome market report provides insights on the current and emerging therapies.

3. Myelodysplastic Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4. Myelodysplastic Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myelodysplastic Syndrome market.

 

Request for free sample report: https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

 

Myelodysplastic Syndrome constitute a group of clonal myeloid neoplasms characterized by anemia or other cytopenias due to ineffective hematopoiesis, abnormal blood, and bone marrow cell morphology, as well as, the risk for clonal evolution and progression to acute myeloid leukemia (AML).

Although the causative agents for MDS are not specific; however a various range of factors such as genetic mutations, exposure to toxic heavy metals, harmful chemicals (such as tobacco, pesticides, and benzene) along with prior exposure to chemotherapy or radiation therapy may act as trigger points.

Currently, the detected recurrent mutations involve nearly 30 genes, which are mainly classified into four functional groups.

Oncogenes/Tumor suppressor genes that constitute common molecular defects in myelodysplastic syndromes are TP53, NRAS, EVI1, and others.

WHO classified MDS into several subtypes, including unilineage dysplasia (SLD), multilineage dysplasia (MLD), ring sideroblasts (RS), excess blasts (EB), isolated del (5q), and unclassifiable (U) depending on the abnormal blood cell production, the number of blast cells and, the likelihood of formation of MDS into AML.

Some patients have MDS cells in their bone marrow even after the treatment, and this condition is called refractory MDS. While some patients have a return of MDS cells in the marrow and a decrease in normal blood cells after remission, which is called a relapse.

Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML.

Refractory MDS is typically treated with a different treatment than the first therapy used, and relapsed MDS is typically treated with either the same treatment used before or a different standard treatment.

No standard exists for the treatment of MDS relapsing after allogeneic stem cell transplantation.

 

“According to DelveInsight’s analysis, males are affected more as compared to females, in case of Myelodysplastic Syndrome (MDS).”

 

Request for free sample report: https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

 

The launch of the emerging therapies is expected to significantly impact the Myelodysplastic Syndrome treatment scenario in the upcoming years:-

Drugs covered

1. Guadecitabine (SGI-110)

2. Rigosertib

3. CC-90009

4. CYAD-02

5. APR-246

And many others

 

The key players in Myelodysplastic Syndrome market are:

1. Astex Pharmaceuticals

2. Onconova Therapeutics

3. Celgene

4. Celyad

5. Aprea Therapeutics

And many others

 

Request for free sample report: https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

 

Table of contents

 

1. Report Introduction

2. Myelodysplastic Syndrome Market Overview at a Glance

3. Myelodysplastic Syndrome Disease Background and Overview

4. Myelodysplastic Syndrome Epidemiology and Patient Population

5. Myelodysplastic Syndrome Country- Wise Epidemiology

6. Myelodysplastic Syndrome Treatments & Medical Practices

7. Myelodysplastic Syndrome Marketed Therapies

8. Myelodysplastic Syndrome Emerging Therapies

9. Key Cross Competition

10. Myelodysplastic Syndrome Market Size

11. 7MM Myelodysplastic Syndrome Country-Wise Market Analysis

12. United States Market Size

13. Germany Market Size

14. France Market Size

15. Italy Market Size

16. Spain Market Size

17. United Kingdom Market Size

18. Japan Market Size

19. Market Drivers

20. Market Barriers

21. Myelodysplastic Syndrome Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles